Back to search results

MRI-Guided Radiation for Metastatic Solid Tumors

This study is looking at a type of radiation treatment called Magnetic Resonance-guided Stereotactic Body Radiation Therapy (MR-guided SBRT) for people with solid tumors that have spread to other parts of the body (metastatic). Researchers want to understand the side effects of this treatment and how well it works. MR-guided SBRT uses special equipment and MRI scans to precisely deliver radiation to tumors, often in a single treatment session, while trying to protect healthy tissues. To join, you must be at least 18 years old, have 1-3 metastatic tumors (not in the brain or spine) that are 5 cm or smaller, and meet certain health criteria. The main goal is to track any serious side effects within three months after treatment. The current status of this study is unclear.

Study design
This is an interventional study planning to enroll 25 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo MR-guided SBRT in one treatment session, along with MRI, CT, and/or PET/CT scans. You would also complete questionnaires.
Compensation
Not stated in the trial record.
Follow-up
After treatment, you would have follow-up visits at 3, 6, 9, and 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07671768

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Tumors, ONE SHOT Trial

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Jonsson Comprehensive Cancer Center
~25 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:Computed TomographyMagnetic Resonance ImagingMRI-guided Stereotactic Body Radiation TherapyPositron Emission TomographyQuestionnaire Administration

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acute toxicity rate
Measured over Up to 3 months post-radiation therapy

Conditions

Metastatic Malignant Solid Neoplasm

Explore related trials

Solid Neoplasm

NCT07671768

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, Californiastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ann Raldow, MD · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center

Who to contact

Carol Felix
[email protected]
310-825-9771
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) 0-2
Histologically confirmed metastatic solid tumor (any primary site)
1-3 metastases ≤ 5 cm each located outside the brain and spine
Lesions treatable at 25-30 Gy × 1 fraction with MR guidance
No overlapping prior radiation
Absolute neutrophil count (ANC) \> 1.5 cell/mm\^3
Hemoglobin (Hgb) \> 8.0 gm/dL
Platelet (PLT) \> 150,000/mm\^3
Total bilirubin \< or equal to 1.5 x upper limit of normal
Aspartate aminotransferase (AST) \< or equal to three times upper limit of normal
Alanine aminotransferase (ALT) \< or equal to three times upper limit of normal
Informed consent obtained

Exclusion

Uncontrolled infection or major comorbidity
Pregnant or breastfeeding
MRI contraindication
Life expectancy \< 3 months

What this trial measures

  • Acute toxicity rateUp to 3 months post-radiation therapy

    Defined as the percentage of patients who experience acute grade ≥ 3 adverse events relating to single-fraction adaptive magnetic resonance-guided stereotactic body radiation therapy. Will be calculated, along with the corresponding 95% Clopper-Pearson exact confidence interval. Assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0